Cardiology Department, Asklepieion General Hospital, Athens, Greece.
First Department of Obstetrics and Gynaecology, Aristotle University, Thessaloniki, Greece.
Curr Pharm Des. 2018;24(46):5537-5541. doi: 10.2174/1381612825666190222144359.
Mineralocorticoid receptor antagonists consist of a class of drugs with pleiotropic beneficial effects in several cardiovascular diseases. However, physicians frequently overlook their use due to the adverse effects of such agents.
To determine the adverse effects of mineralocorticoid receptor antagonists and to suggest clinically meaningful options. We present data on the two most administered agents of this class: spironolactone and eplerenone.
We conducted an in-depth review of the existing international literature to draft a mini review about the mineralocorticoid receptor antagonists-related side effects.
Mineralocorticoid receptor antagonists are associated with increased risk of hyperkalemia and acute deterioration of renal function. Of note, these adverse effects are dose-dependent, more common during the initial period of treatment, and are usually reversed after the withdrawal of therapy. Sex-related adverse events are noted mainly in spironolactone while switching to eplerenone could attenuate those.
Mineralocorticoid receptor antagonists therapy is significantly limited due to their side effects. The development of novel non-steroidal mineralocorticoid receptor antagonists could substantially widen the use of such agents.
醛固酮受体拮抗剂属于一类具有多种心血管疾病有益作用的药物。然而,由于这些药物的不良反应,医生经常忽略它们的使用。
确定醛固酮受体拮抗剂的不良反应,并提出有临床意义的选择。我们提供了该类药物中两种使用最多的药物的数据:螺内酯和依普利酮。
我们对现有的国际文献进行了深入审查,以撰写一篇关于醛固酮受体拮抗剂相关副作用的迷你综述。
醛固酮受体拮抗剂与高钾血症和肾功能急性恶化的风险增加有关。值得注意的是,这些不良反应是剂量依赖性的,在治疗的初始阶段更为常见,并且通常在停药后逆转。性别的不良反应主要见于螺内酯,而转换为依普利酮可以减轻这些不良反应。
由于其副作用,醛固酮受体拮抗剂的治疗受到显著限制。新型非甾体醛固酮受体拮抗剂的开发可以大大扩大这些药物的应用。